Sale of Biogen not necessarily bad for Massachusetts

CAMBRIDGE, Mass. Sources believe there is a very good chance that biotech company Biogen will be sold, but that does not necessarily mean a hit to the Massachusetts’s economy, according to boston.com

The problem is that, there are a lot of holdups depending on who buys the company and with contracts the company has right now with other companies concerning some of its drugs.

Elan and Biogen have an agreement on the multiple sclerosis drug Tysarbi, which states that if Biogen is bought, the company has the right to acquire Biogen’s interest in the treatment. The same goes for Genentech with the drug Rituxen, a treatment for non-Hodgkins lymphoma and rheumatoid arthritis.

Also, if Biogen is purchased, whoever acquires it may decide to break up the company. Pfizer, one of the companies interested in buying Biogen already has its own research centers and sales force and would therefore not need to keep Biogen going at full force. It remains to be seen what the company, if it even decided to go up for sale at all.

Poll

Poll

Which of the current U.S. Presidential hopefuls do you think would be best for your business?

Hillary Clinton

Jeb Bush

Donald Trump

Ted Cruz

Ben Carson

Scott Walker

Marco Rubio

Rand Paul

Chris Christie

Mike Huckabee

SPECIAL REPORTS

Pharmacy’s battle for recognition continues

Fifty years ago this summer, President Lyndon B. Johnson secured his place in history by signing into law the legislation that created Medicare and Medicaid. To commemorate the anniversary, Drug Store News has put together an exclusive report on the effect that Medicare and Medicaid have had on the retail pharmacy industry and how it has transformed the role of the pharmacist. more...

IN THIS ISSUE

In this issue, DSN profiles Rite Aid and how the company is achieving a vision to become a retail healthcare company that delivers a higher level of care to its communities; takes you on a tour of Sears; offers insight into millennial shoppers and more. Click here to view the issue.